(Q36364388)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16402079%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

review article

1 reference

title

Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16402079%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16402079%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

Marco A. Riva

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16402079%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Racagni G

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16402079%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

1 March 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16402079%20AND%20SRC:MED&resulttype=core&format=json

The Pharmacogenomics Journal

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16402079%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16402079%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16402079%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

95-104

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16402079%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.tpj.6500360

15 January 2020

exact match

0 references

cites work

Molecular pathogenesis of Parkinson disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Neurodegeneration and neuroprotection in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

BDNF gene expression is reduced in the frontal cortex of dopamine transporter knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Evaluation of nigrostriatal dopaminergic function in adult +/+ and +/- BDNF mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Striatal dopamine output is compromised within +/- BDNF mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

BDNF is induced by wild-type alpha-synuclein but not by the two mutants, A30P or A53T, in glioma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Reduced expression of brain-derived neurotrophic factor protein in Parkinson's disease substantia nigra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson's disease and age of onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Lack of association between the BDNF Val66Met polymorphism and Parkinson's disease in a Swedish population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Distribution of intracerebral ventricularly administered neurotrophins in rat brain and its correlation with trk receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Immortalized neural progenitor cells for CNS gene transfer and repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Neural transplantation for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Neuropathology of fetal nigra transplants for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Gene therapy for neurological disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Brain-derived neurotrophic factor transgenic mice exhibit passive avoidance deficits, increased seizure severity and in vitro hyperexcitability in the hippocampus and entorhinal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Decreased BDNF signalling in transgenic mice reduces epileptogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Exacerbated status epilepticus and acute cell loss, but no changes in epileptogenesis, in mice with increased brain-derived neurotrophic factor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Dopaminergic stimulation up-regulates the in vivo expression of brain-derived neurotrophic factor (BDNF) in the striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Anterograde transport of brain-derived neurotrophic factor and its role in the brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Attenuation of MPTP-induced dopaminergic neurotoxicity by TV3326, a cholinesterase-monoamine oxidase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Parkinson's disease: is the initial treatment established?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Dopaminergic D2 receptor activation modulates FGF-2 gene expression in rat prefrontal cortex and hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

The high molecular weight fibroblast growth factor-2 isoforms (21,000 mol. wt and 23,000 mol. wt) mediate neurotrophic activity on rat embryonic mesencephalic dopaminergic neurons in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

The neuroprotective agent memantine induces brain-derived neurotrophic factor and trkB receptor expression in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

mGluRs: a target for pharmacotherapy in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Modulation of dendritic release of dopamine by metabotropic glutamate receptors in rat substantia nigra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+-induced neurotoxicity along with brain-derived neurotrophic factor induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Selective activation of group-II metabotropic glutamate receptors is protective against excitotoxic neuronal death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Beneficial effects of nicotine and cigarette smoking: the real, the possible and the spurious

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Nicotine and nicotinic receptors; relevance to Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Parkinson's disease protects against smoking?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Smoking, nicotine and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Smoking, alcohol, and coffee consumption preceding Parkinson's disease: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

The nicotinic acetylcholine receptor: structure and autoimmune pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Nicotine administration reduces striatal MPP+ levels in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Hippocampal neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Acute nicotine decreases, and chronic nicotine increases the expression of brain-derived neurotrophic factor mRNA in rat hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

The small molecule FKBP ligand GPI 1046 induces partial striatal re-innervation after intranigral 6-hydroxydopamine lesion in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Immunosuppressive (FK506) and non-immunosuppressive (GPI1046) immunophilin ligands activate neurotrophic factors in the mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Hydrophobic dipeptide Leu-Ile protects against neuronal death by inducing brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Systemic treatment with GPI 1046 improves spatial memory and reverses cholinergic neuron atrophy in the medial septal nucleus of aged mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Neurotrophic and neuroprotective effects of tripchlorolide, an extract of Chinese herb Tripterygium wilfordii Hook F, on dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Turning cells red: signal transduction mediated by erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Erythropoietin exerts neuroprotective effect in neonatal rat model of hypoxic-ischemic brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Erythropoietin treatment improves neurological functional recovery in EAE mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Erythropoietin restores glutathione peroxidase activity in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced neurotoxicity in C57BL mice and stimulates murine astroglial glutathione peroxidase production in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Erythropoietin protects primary hippocampal neurons increasing the expression of brain-derived neurotrophic factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Cannabinoid receptor activation and elevated cyclic AMP reduce glutamate neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta-tetrahydrocannabinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Therapeutic value of exercise training in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Effectiveness of exercise therapy: a best-evidence summary of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Exercise enhances learning and hippocampal neurogenesis in aged mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Environmental enrichment in adulthood eliminates neuronal death in experimental Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Voluntary exercise induces a BDNF-mediated mechanism that promotes neuroplasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Hippocampal BDNF mediates the efficacy of exercise on synaptic plasticity and cognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Exercise pre-conditioning reduces brain damage in ischemic rats that may be associated with regional angiogenesis and cellular overexpression of neurotrophin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Treadmill training ameliorates dopamine loss but not behavioral deficits in hemi-parkinsonian rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Dopamine depletion alters phosphorylation of striatal proteins in a model of Parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Brain-derived neurotrophic factor regulates maturation of the DARPP-32 phenotype in striatal medium spiny neurons: studies in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Role of phosphatidylinositide 3-kinase in brain-derived neurotrophic factor-induced DARPP-32 expression in medium size spiny neurons in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

A calcium/calmodulin kinase pathway connects brain-derived neurotrophic factor to the cyclic AMP-responsive transcription factor in the rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Brain-derived growth factor and glial cell line-derived growth factor use distinct intracellular signaling pathways to protect PD cybrids from H2O2-induced neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Activity-dependent modulation of the BDNF receptor TrkB: mechanisms and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Reduced BDNF mRNA Expression in the Parkinson's Disease Substantia Nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

Neurotrophic factors in Alzheimer's and Parkinson's disease brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021

Re-evaluation of the role of the dopamine transporter in dopamine system homeostasis1Published on the World Wide Web on 27 January 1998.1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021

Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021

Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021

In situ gelling hydrogels for conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021

Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021

Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021

Functional interactions between somatodendritic dopamine release, glutamate receptors and brain-derived neurotrophic factor expression in mesencephalic structures of the brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021

Metabotropic glutamate receptors prevent nitric oxide-induced programmed cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021

Cigarette smoking and Parkinson disease: 1. Comparison of cases with matched neighbors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021

Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021

Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021

Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021

Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021

Antidepressant drug exposure is associated with mRNA levels of tyrosine receptor kinase B in major depressive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021

Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021

Decreased phosphorylation levels of TrkB neurotrophin receptor in the spinal cords from patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500360

7 January 2021